Future Research and Monitoring Priorities
Research regarding ERVEBO is ongoing, including safety of ERVEBO in immunocompromised persons, pregnant women, and children. The same considerations and recommendations for these special populations apply as in the initial recommendations. In addition, long-term studies are continuing to assess immunogenicity and duration of protection. ACIP will consider these data as they become available and revise recommendations accordingly.
Members of the Advisory Committee on Immunization Practices; member roster as of November 2021 is available (https://www.cdc.gov/vaccines/acip/members/index.html).
Morbidity and Mortality Weekly Report. 2022;71(8):290-292. © 2022 Centers for Disease Control and Prevention (CDC)